We are live on
!
Find out more
Perceptive Advisors Portfolio holdings
AUM
$6.66B
Turnover
32.23%
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.54%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$5.12B
AUM Growth
-$493M
(-8.8%)
Cap. Flow
-$685M
Cap. Flow
% of AUM
-13.38%
Top 10 Holdings %
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42
Avg Time Held Equity + Options
1.5
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
0.7
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$101M |
| 2 |
Relay Therapeutics
RLAY
|
+$70.2M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$59.9M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$39.8M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$33.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exact Sciences
EXAS
|
+$122M |
| 2 |
Arcellx
ACLX
|
+$95.6M |
| 3 |
Boston Scientific
BSX
|
+$93.3M |
| 4 |
Amicus Therapeutics
FOLD
|
+$90.7M |
| 5 |
Astria Therapeutics
ATXS
|
+$84.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.61% |
| 2 | Miscellaneous | 1.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
101
Boston Scientific
BSX
$64B
| – | – |
-979,000
| Closed | -$93.3M | – |
|
102
CALL
Capricor Therapeutics
CAPR
$423M
| – | – |
-242,100
| Closed | -$6.99M | – |
|
103
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-165,131
| Closed | -$36.5M | – |
|
104
CVS Health
CVS
$118B
| – | – |
-220,000
| Closed | -$17.5M | – |
|
105
Danaher
DHR
$163B
| – | – |
-200,000
| Closed | -$45.8M | – |
|
106
DexCom
DXCM
$33.1B
| – | – |
-225,758
| Closed | -$15M | – |
|
|
107
DELISTED
Exact Sciences
EXAS
| – | – |
-1,200,487
| Closed | -$122M | – |
|
|
108
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-6,370,851
| Closed | -$90.7M | – |
|
109
Glaukos
GKOS
$9.77B
| – | – |
-140,000
| Closed | -$15.8M | – |
|
110
Gossamer Bio
GOSS
$54.4M
| – | – |
-39,246
| Closed | -$9.73M | – |
|
111
Immix Biopharma
IMMX
$720M
| – | – |
-338,941
| Closed | -$1.77M | – |
|
112
Iovance Biotherapeutics
IOVA
$6.67B
| – | – |
-152,714
| Closed | -$417K | – |
|
113
Disc Medicine
IRON
$2.17B
| – | – |
-450,743
| Closed | -$35.8M | – |
|
114
Kodiak Sciences
KOD
$5.54B
| – | – |
-848,900
| Closed | -$23.7M | – |
|
115
Krystal Biotech
KRYS
$9.77B
| – | – |
-17,500
| Closed | -$4.31M | – |
|
116
Kymera Therapeutics
KYMR
$8.99B
| – | – |
-69,935
| Closed | -$5.44M | – |
|
117
Lexeo Therapeutics
LXEO
$227M
| – | – |
-139,835
| Closed | -$1.39M | – |
|
118
Mirum Pharmaceuticals
MIRM
$5.35B
| – | – |
-259,545
| Closed | -$20.5M | – |
|
119
enVVeno Medical
NVNO
$5.5M
| – | – |
-50,258
| Closed | -$564K | – |
|
120
Olema Pharmaceuticals
OLMA
$601M
| – | – |
-165,713
| Closed | -$4.14M | – |
|
121
Penumbra
PEN
$12.7B
| – | – |
-110,529
| Closed | -$34.4M | – |
|
122
PepGen
PEPG
$175M
| – | – |
-829,870
| Closed | -$5.4M | – |
|
123
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-825,890
| Closed | -$28M | – |
|
124
Schrodinger
SDGR
$1.91B
| – | – |
-202,400
| Closed | -$3.62M | – |
|
125
Savara
SVRA
$974M
| – | – |
-2,400,000
| Closed | -$14.5M | – |
|
Similar funds
Perceptive Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Perceptive Advisors withdrew a net $685M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Miscellaneous.
Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.
- Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
- Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
- Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
- Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
- Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
- Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
- Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.